N-ethyl-N-methylneopentylamine | 26153-85-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-ethyl-N-methylneopentylamine
• 英文别名: N-ethyl-N,2,2-trimethylpropan-1-amine
• CAS: 26153-85-5
• 化学式: C₈H₁₉N
• 分子量: 129.246
• InChiKey: MZNVHKWACQNDAX-UHFFFAOYSA-N

物化性质

• 沸点：
  128.3±8.0 °C(Predicted)
• 密度：
  0.769±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-甲基三甲基乙酰胺 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 丙酮 为溶剂， 生成 N-ethyl-N-methylneopentylamine
  参考文献：
  名称：

  Stevens rearrangements of N,N,N-trimethylneopentylammonium iodide

  摘要：

  DOI：

  10.1021/jo00836a015

文献信息

• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS D'IDO
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015031295A1

  公开（公告）日：2015-03-05

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

  所公开的化合物能够调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性，包含该化合物的药物组合物以及使用本发明的化合物治疗增殖性疾病的方法，如癌症、病毒感染和/或自身免疫疾病。
• AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shen Jianhua

  公开号：US20140171431A1

  公开（公告）日：2014-06-19

  The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA 2 enzyme activities, wherein each substituent is as defined in the specification.

  本发明涉及制药化学领域，特别是一种由通式（I）、（II）或（III）表示的新型类唑化合物，以及其制备方法，以这些化合物为活性成分的药物组合物，以及在制备用于治疗与Lp-PLA2酶活性相关疾病的药物中使用这些唑化合物和药物组合物的用途，其中每个取代基如规范中定义。
• OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT
  申请人：Tokunaga Teruhisa

  公开号：US20090131398A1

  公开（公告）日：2009-05-21

  Disclosed is a compound represented by the formula (1) below, a prodrug thereof or a pharmaceutically acceptable salt of either, which is useful as a therapeutic, preventive or ameliorating agent for diabetes and the like. (In the formula, R 3 represents an optionally substituted carbamoyl group or the like; X represents a hydroxyl group or the like; W 1 and W 2 independently represent a single bond or methylene; R 7 and R 8 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; and Ar represents an optionally substituted aryl group or the like.)

  本发明揭示了一种化合物，其化学式表示为(1)，或其前药或药学上可接受的盐，用作治疗、预防或改善糖尿病等疾病的治疗剂、预防剂或改善剂。（其中，R3代表可选取代的氨基甲酰基或类似基团；X代表羟基或类似基团；W1和W2独立地代表单键或亚甲基；R7和R8独立地代表氢原子、可选取代的烷基或类似基团；Ar代表可选取代的芳基或类似基团。）
• LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Wakiyama Yoshinari

  公开号：US20100210570A1

  公开（公告）日：2010-08-19

  An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R 1 represents N-optionally substituted C 1-6 alkyl-N-optionally substituted C 1-6 alkylamino-C 1-6 alkyl; R 2 represents a hydrogen atom or optionally substituted C 1-6 alkyl; R 3 represents optionally substituted C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供以下化合物(1)或其药理学上可接受的盐或溶剂，其中A代表芳基；R1代表N-可选取代的C1-6烷基-N-可选取代的C1-6烷基氨基-C1-6烷基；R2代表氢原子或可选取代的C1-6烷基；R3代表可选取代的C1-6烷基或C3-6环烷基-C1-4烷基；m为1至3；n为0；p为0至2。这些化合物是新颖的林可霉素衍生物，对最近在感染性疾病治疗中引起问题的耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物药物，有助于预防或治疗细菌感染性疾病。
• Tetracycline Compounds
  申请人：Deng Yonghong

  公开号：US20120208788A1

  公开（公告）日：2012-08-16

  The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

  本发明涉及一种由结构式（1）表示的化合物或其药学上可接受的盐。结构式（I）的变量在此定义。本发明还描述了包含结构式（I）化合物的药物组合物及其治疗用途。